Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 901–1,000 of 1,006
Ohba, T., Toyokawa, G., Kometani, T., Nosaki, K., Hirai, F., Yamaguchi, M., Hamatake, M., Seto, T., Ichinose, Y., & Sugio, K. (2013) · Surgery Today · doi:10.1007/s00595-013-0589-2 · Cited by 36
“At least four other effector classes have demonstrated roles in Ras transformation, as assessed in cell culture and mouse models of cancer; these are the p110 catalytic subunits (p110a, b, c, and d) of class I phosphatidylinositol 3 kinases (PI3K), the Tiam1 Rac small GTPase-specific GEF, the Ral small GTPase-specific…”
BackgroundLee, S. J., Kang, B. W., Chae, Y. S., Kim, H. J., Park, S., Park, J. S., Choi, G., Jeon, H.-S., Lee, W. K., & Kim, J. G. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3729-z · Cited by 36
“TSC1 and TSC2 link the upstream growth factor signaling to mTOR and negatively regulate cell expression and b-catenin signaling activity.(17,18) Plus, TSC2, also known as tuberin, has been shown to be specifically involved in insulin signaling, tumor-suppressor functions, and regulating cell growth.”
BackgroundKim, R., Kim, S., Roh, K., Park, S., Park, J.-R., Kang, K., Kong, G., Tang, B., Yang, Y.-A., Kohn, E. A., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.010 · Cited by 36
“The Ras-induced signaling pathway is mediated by multiple downstream proteins, and is cross-regulated with various factors including, other small GTPases [41].”
BackgroundRehan, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219180 · Cited by 36
A Systems Biology Roadmap to Decode mTOR Control System in Cancer
Dorvash, M., Farahmandnia, M., & Tavassoly, I. (2019) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-019-00347-6 · Cited by 37
mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy
Pazhooh, R. D., Farnood, P. R., Asemi, Z., Mirsafaei, L., Yousefi, B., & Mirzaei, H. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103142 · Cited by 42
Liver Regeneration and Immunity: A Tale to Tell
Di-Iacovo, N., Pieroni, S., Piobbico, D., Castelli, M., Scopetti, D., Ferracchiato, S., Fazia, M. A. D., & Servillo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021176 · Cited by 47
“Certainly, the mTOR1 complex (mTORC1) is the main target of AKT, which regulates protein synthesis, depending on nutrient availability and in response to growth factors [109].”
BackgroundWill Kinase Inhibitors Make it as Glioblastoma Drugs?
Mellinghoff, I. K., Schultz, N. D., Mischel, P. S., & Cloughesy, T. F. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_178 · Cited by 41
“Their critical role in the pathogenesis of human cancer was fully recognized following the discovery that many human tumors harbor mutations in genes whose gene products regulate levels of the lipid molecule PIP3 (Shaw and Cantley 2006; Vogt et al. 2009).”
BackgroundInfluentialCostantini, J. L., Cheung, S., Hou, S., Li, H., Kung, S. K. P., Johnston, J. B., Wilkins, J. A., Gibson, S. B., & Marshall, A. J. (2009) · Blood · doi:10.1182/blood-2009-03-213058 · Cited by 36
Murugan, A. K., Hồng, N. T., Cuc, T. T. K., Hung, N. C., Munirajan, A. K., Ikeda, M., & Tsuchida, N. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.05.638 · Cited by 36
Sushma, P. S., Jamil, K., Kumar, P. U., Satyanarayana, U., Ramakrishna, M., & Triveni, B. (2015) · Tumor Biology · doi:10.1007/s13277-015-4648-8 · Cited by 36
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents
Serkova, N. J., & Eckhardt, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00152 · Cited by 38
May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs?
Ravera, M., Gabano, E., Tinello, S., Zanellato, I., & Osella, D. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.11.024 · Cited by 37
Quantitative Measurement of Phosphatidylinositol 3,4,5-trisphosphate
Guillou, H., Stephens, L., & Hawkins, P. T. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)34007-x · Cited by 41
“, PTEN) has attracted interest in trying to inhibit this pathway as a novel approach to cancer therapy (Cully et al., 2006; Shaw and Cantley, 2006; Stephens et al., 2005).”
BackgroundPopulation Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1
Scott, J. R., Courter, J. D., Saldaña, S. N., Widemann, B. C., Fisher, M. J., Weiss, B., Perentesis, J. P., & Vinks, A. A. T. M. M. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318286dd3f · Cited by 36
Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, ΔTrkA
Meyer, J., Rhein, M., Schiedlmeier, B., Kustikova, O. S., Rudolph, C., Kamino, K., Neumann, T., Yang, M., Wahlers, A., Fehse, B., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404882 · Cited by 38
Small Molecule Inhibitors of the PI3-Kinase Family
Knight, Z. A. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_44 · Cited by 43
Azaro, A., Rodon, J. A., Calles, A., Braña, I., Hidalgo, M. M., Lopez-Casas, P. P., Muñoz, M., Westwood, P., Miller, J. A., Moser, B. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0241-7 · Cited by 35
The change tendency of PI3K/Akt pathway after spinal cord injury.
Zhang, P., Zhang, L., Zhu, L., Chen, F., Zhou, S., Tian, T., Zhang, Y., Jiang, X., Li, X., Zhang, C., et al. (2015) · PubMed Central · Cited by 35
miR-205 as a biological marker in non-small cell lung cancer
Duan, B., Guo, T., Sun, H., Cai, R., Rui, Q., & Xi, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.086 · Cited by 35
GH and GHR signaling in human disease
Guevara‐Aguirre, J., Guevara, A., Palacios, I., Pérez, M. Q., Prócel, P., & Terán, E. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.12.006 · Cited by 39
Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration
Bencze, J., Mórotz, G. M., Seo, W., Bencs, V., Kalman, J. L., Miller, C. C. J., & Hortobágyi, T. (2018) · Molecular Brain · doi:10.1186/s13041-018-0363-x · Cited by 36
Zhou, X., Shang, Y., Lu, R., Fan, C., & Mo, X. (2019) · Future Oncology · doi:10.2217/fon-2018-0920 · Cited by 35
Peng, X., Liu, Y., Zhu, S., Peng, X., Li, H., Jiao, W., Lin, P., Zhang, Z., Qiu, Y., Jin, M., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03047-2 · Cited by 37
Current therapeutic targets and multifaceted physiological impacts of caffeine
Song, X., Kirtipal, N., Lee, S., Malý, P., & Bharadwaj, S. (2023) · Phytotherapy Research · doi:10.1002/ptr.8000 · Cited by 36
“…of PI3Ks are scrutinized and modulated by internal signals, such as PTEN (phosphatase and tensin homolog deleted from chromosome 10), under normal conditions, but deregulation of these proteins has been recognized in one third of human cancer development (Arteaga, 2010; Shaw & Cantley, 2006).”
BackgroundAndersen, R. K., Hammer, K., Hager, H., Christensen, J. N., Ludvigsen, M., Honoré, B., Thomsen, M. H., & Madsen, M. M. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12352 · Cited by 38
“The Akt pathway regulates four intersecting biological processes: cell survival, cell cycle progression, cell growth, and cell metabolism (Shaw and Cantley, 2006).”
BackgroundJones, D. R., Keune, W., Anderson, K. E., Stephens, L., Hawkins, P. T., & Divecha, N. (2014) · FEBS Journal · doi:10.1111/febs.12879 · Cited by 38
Ni, B., Wen, L.-B., Wang, R., Hao, H.-P., Huan, C., Wang, X., Huang, L. P., Miao, J., Fan, H., & Mao, X. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.126 · Cited by 37
Guanylyl Cyclase C in Colorectal Cancer: Susceptibility Gene and Potential Therapeutic Target
Lin, J. E., Li, P., Pitari, G. M., Schulz, S., & Waldman, S. A. (2009) · Future Oncology · doi:10.2217/fon.09.14 · Cited by 36
Sarnelli, G., Gigli, S., Capoccia, E., Iuvone, T., Cirillo, C., Seguella, L., Nobile, N., D’Alessandro, A., Pesce, M., Steardo, L., et al. (2016) · Phytotherapy Research · doi:10.1002/ptr.5601 · Cited by 37
Xu, Y., & Lv, S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.040 · Cited by 35
AMP-activated protein kinase and energy balance in breast cancer.
Zhao, H., Orhan, Y. C., Zha, X., Esencan, E., Chatterton, R. T., & Bulun, S. E. (2017) · Europe PMC (PubMed Central) · Cited by 48
Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling
Lackey, J., Barnett, J., Davidson, L., Batty, I. H., Leslie, N. R., & Downes, C. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210520 · Cited by 38
“…activity of the PI 3-kinase/Akt signaling pathway, caused most frequently by mutation of the PI 3-kinase subunit p110a, or loss of the opposing tumor suppressor phosphatase, PTEN (Cully et al., 2006; Shaw and Cantley, 2006), leading to increased growth, survival and proliferation of tumor cells.”
Bruhn, M. A., Townsend, A. R., Lee, C. K., Shivasami, A., Price, T. J., Wrin, J., Arentz, G., Tebbutt, N. C., Hocking, C. M., Cunningham, D., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28698 · Cited by 33
Mori, N., Kyo, S., Sakaguchi, J., Mizumoto, Y., Ohno, S., Maida, Y., Hashimoto, M., Takakura, M., & Inoue, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00630.x · Cited by 34
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693
Kumar, R., Blakemore, S. J., Ellis, C. E., Petricoin, E. F., Pratt, D. R., Macoritto, M. P., Matthews, A. L., Loureiro, J., & Elliston, K. O. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-419 · Cited by 37
“Discussion The AKT family of kinases has been well characterized as a mediator of cell proliferation and survival, and these functionalities highlight the role of these kinases in tumor progression [2,3].”
BackgroundTyrosine kinase pathways modulate tumor susceptibility to natural killer cells
Bellucci, R., Nguyen, H.-N. P., Martin, A. M., Heinrichs, S., Schinzel, A. C., Hahn, W. C., & Ritz, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58457 · Cited by 34
“IGF1R, a tyrosine kinase receptor, has been identified as a target for cancer therapy (20), and several studies have shown that binding of IGF to IGF1R can induce phosphorylation of RAF1 and PI3K, resulting in downstream activation of MAPK and PI3K/Akt pathways (21).”
BackgroundPhosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Błajecka, K., Borgström, A., & Arcaro, A. (2011) · Current Drug Targets · doi:10.2174/138945011795677773 · Cited by 36
“Activated Ras is also known to stimulate PI3Ks by directly binding to the catalytic subunit p110 [35].”
BackgroundNew and emerging factors in tumorigenesis: an overview
Kim, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s47797 · Cited by 43
Signal transduction inhibitors and antiangiogenic therapies for malignant glioma
Mellinghoff, I. K., Lassman, A. B., & Wen, P. Y. (2011) · Glia · doi:10.1002/glia.21137 · Cited by 38
“This is particularly true for the RAS/RAF cascade and the phosphatidylinositol-3OH kinase (PI(3)K)/AKT signaling pathway (Shaw and Cantley, 2006).”
BackgroundAdvances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
Mattos‐Arruda, L. D., & Cortés, J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0187 · Cited by 35
“The mammalian target of rapamycin (mTOR) is involved in the cellular processes that contribute to the development and progression of breast cancer [104].”
BackgroundLin, L., Zhou, Y., Li, Y., Wang, L., Sun, L., Zhou, L., Arai, H., Qi, Y., & Yang, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.02.013 · Cited by 38
Huijts, C. M., Lougheed, S. M., Bodalal, Z., van Herpen, C. M., Hamberg, P., Tascilar, M., Haanen, J. B. A. G., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2288-8 · Cited by 35
Zhang, W., Lu, C., Cai, S., Feng, Y., Shan, J., & Di, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870282 · Cited by 39
“As an oncogenic protein, the activation of AKT is a general molecular biological feature in cancer (Hennessy et al., 2005; Shaw and Cantley, 2006; Song et al., 2019).”
BackgroundThaler, S., Thiede, G., Hengstler, J. G., Schad, A., Schmidt, M., & Sleeman, J. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29404 · Cited by 35
“Akt suppresses cell death in a number of ways (37), including activation of NF-kB and transactivation of anti-apoptotic NF-kB target genes, as well as suppression of the transcriptional activity of forkhead transcription factors such as Foxo3A.”
BackgroundWang, X., Li, G., Koul, S., Ohki, R., Maurer, M., Borczuk, A., & Halmos, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3674 · Cited by 36
Lin, F., Buil, L. C. M., Sherris, D., Beijnen, J. H., & van Tellingen, O. (2013) · International Journal of Cancer · doi:10.1002/ijc.28126 · Cited by 37
Targeting bone metastatic cancer: Role of the mTOR pathway
Bertoldo, F., Silvestris, F., Ibrahim, T., Cognetti, F., Generali, D., Ripamonti, C. I., Amadori, D., Colleoni, M. A., Conte, P., Mastro, L. D., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.009 · Cited by 35
Enzenmüller, S., Gonzalez, P., Karpel‐Massler, G., Debatin, K., & Fulda, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.007 · Cited by 35
Cozzi, M., Giorgi, F. D., Marcelli, E., Pentimalli, F., Forte, I. M., Schenone, S., D’Urso, V., Falco, G. D., Botta, M., Giordano, A., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19519 · Cited by 37
Moro, L., Arbini, A., Marra, E., & Greco, M. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.1.217 · Cited by 41
Liao, S., Ruiz, Y., Gulzar, H., Yelskaya, Z., Taouit, L. A., Houssou, M., Jaikaran, T., Schvarts, Y., Kozlitina, K., Basu-Roy, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171256 · Cited by 37
Kim, S. T., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Kang, W. K., & Lim, H. Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3196-6 · Cited by 37
“mTOR is composed of two distinct protein complexes, mTORC1 and mTORC2, that act on different levels of the pathway [24, 25].”
BackgroundTimp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma
Toricelli, M., de Melo, F. H. M., Hunger, A., Zanatta, D. B., Strauss, B. E., & Jasiulionis, M. G. (2017) · Cancers · doi:10.3390/cancers9040037 · Cited by 34
“However, the complete activation occurs only when serine 473 is phosphorylated by the mTORC2 complex [5].”
BackgroundNuclear Envelope Regulation of Signaling Cascades
Choi, J. C., & Worman, H. J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-8032-8_9 · Cited by 35
Bański, P., Mahboubi, H., Kodiha, M., Shrivastava, S., Kanagaratham, C., & Stochaj, U. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117291 · Cited by 40
Ras sumoylation in cell signaling and transformation
Dai, W., Xie, S., Chen, C., & Choi, B. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.033 · Cited by 27
Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence
Wang, X., Min, S., Liu, H., Wu, N., Liu, X., Wang, T., Li, W., Shen, Y., Wang, H., Qian, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809856 · Cited by 33
“As NF1 is a negative regulator of RAS/PI3K/Akt signaling (Shaw & Cantley, 2006), the loss of NF1 function in Kras ; Nf1 -mutant LUAD cells likely results in overactive RAS/PI3K/Akt signaling and heightened dependence on glycolysis.”
Shen, Q., Stanton, M., Feng, W., Rodriguez, M. E., Ramondetta, L. M., Chen, L., Brown, R. E., & Duan, X. (2010) · PubMed · Cited by 41
Molecular alterations associated with liver metastases development in colorectal cancer patients
Bruin, S., He, Y., Mikolajewska-Hanclich, I., Liefers, G., Klijn, C. N., Vincent, A. D., Verwaal, V. J., de Groot, K., Morreau, H., van Velthuysen, M. F., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.184 · Cited by 38
“This pathway has a central role in tumorigenesis by regulating cell growth, differentiation and apoptosis (Vivanco and Sawyers, 2002; Samuels et al, 2004; Shaw and Cantley, 2006).”
BackgroundWeckman, A. M., Rotondo, F., Ieva, A. D., Syro, L. V., Butz, H., Cusimano, M. D., & Kovács, K. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0042 · Cited by 34
Shi, J.-J., Chen, S.-M., Guo, C.-L., Li, Y., Ding, J., & Meng, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.181 · Cited by 33
Chu, D., & Zhang, Z. (2018) · Molecules · doi:10.3390/molecules23102409 · Cited by 33
“The PI3K signaling pathway is an essential signaling cascade that promotes cell survival [48].”
BackgroundLiu, M., Huang, X., Tian, Y., Xiao, Y., Wang, F., Chen, J., Zhang, Q., Zhang, Q., & Yuan, X. H. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11105 · Cited by 33
Helwa, A. A., El‐Dydamony, N. M., Radwan, R. A., Abdelraouf, S. M., & Abdelnaby, R. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104051 · Cited by 35
Jaglanian, A., Termini, D., & Tsiani, E. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110717 · Cited by 38
Anti-carcinogenic effects of exercise-conditioned human serum: evidence, relevance and opportunities
Metcalfe, R. S., Kemp, R. N., Heffernan, S. M., Churm, R., Chen, Y., Ruffino, J. S., Conway, G. E., Tornillo, G., & Orange, S. T. (2021) · European Journal of Applied Physiology · doi:10.1007/s00421-021-04680-x · Cited by 39
“The proteins in this pathway are also commonly dysregulated, and hence hyperactive, in a large proportion of different cancer types (Shaw and Cantley 2006).”
BackgroundInfluentialZhu, X., Peng, S.-Q., Wang, L., Chen, X., Feng, C.-X., Liu, Y.-Y., & Chen, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04201-w · Cited by 38
Park, H.-Y., Aiyar, S. E., Fan, P., Wang, J., Yue, W., Okouneva, T., Cox, C., Jordan, M. A., Demers, L. M., Cho, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0056 · Cited by 33
“However, additional primary effects of TMS on other targets such as FAK, Akt, and mTOR might also be possible (32, 33).”
BackgroundCherla, R. P., Lee, S.-Y., Mulder, R. A., Lee, M., & Tesh, V. L. (2009) · Infection and Immunity · doi:10.1128/iai.00738-09 · Cited by 33
“Changes in membrane phospholipids localize kinases containing pleckstrin homology domains to the membrane, including PDK1 and Akt (4, 43).”
BackgroundGeneral morphological and biological features of neoplasms: integration of molecular findings
Díaz-Cano, S. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02937.x · Cited by 37
“link between mTOR signalling and tumorigenesis ⁄ cell proliferation.(81,82)”
BackgroundŠálek, C., Mináriková, P., Benešová, L., Nosek, V., Strnad, R., Zavoral, M., & Minárik, M. (2009) · PubMed · Cited by 33
Exosomal miRs in Lung Cancer: A Mathematical Model
Lai, X., & Friedman, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167706 · Cited by 36
AZD8055 Exerts Antitumor Effects on Colon Cancer Cells by Inhibiting mTOR and Cell-cycle Progression
Chen, Y., Lee, C.-H., Tseng, B.-Y., Tsai, Y., Tsai, H., Yao, C., & Tseng, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12369 · Cited by 34
Adrenomedullin, a Novel Target for Neurodegenerative Diseases
Ferrero, H., Larráyoz, I. M., Gil-Bea, F. J., Martínez, A., & Ramírez, M. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1031-y · Cited by 34
Rajasinghe, L. D., Hutchings, M., & Gupta, S. V. (2019) · Metabolites · doi:10.3390/metabo9030050 · Cited by 33
Edros, R. Z., McDonnell, S., & Al‐Rubeai, M. (2014) · BMC Biotechnology · doi:10.1186/1472-6750-14-15 · Cited by 40
RAS GTPases are modified by SUMOylation
Choi, B. H., Chen, C., Philips, M., & Dai, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23269 · Cited by 32
“RAS proteins are GTPases that participate in multiple signal cascades, regulating crucial cellular processes including cell survival, proliferation, differentiation, and autophagy [2, 5, 6].”
YI, B.-R., CHOI, K. J., KIM, S. U., & CHOI, K.-C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1523 · Cited by 32
“important lipid second messenger that has a role in tumorigenesis (50).”
BackgroundLü, X. Q., Wang, X., Cheng, H., Wang, X., Liu, C., & Tan, X. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2210845 · Cited by 34
PDK1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models
Ellwood‐Yen, K., Keilhack, H., Kunii, K., Dolinski, B. M., Connor, Y., Hu, K., Nagashima, K., O’Hare, E., Erkul, Y., Bacco, A. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2282 · Cited by 34
“Targeted ES cell lines were treated with doxycycline for 2 days (1 g/kg), followed by PDK1specific reverse transcriptase PCR (RT-PCR) to identify shRNA constructs with efficient knockdown (shPDK1: 50-GGCTAGAGATCTTGTGGAA-30; shPDK1(2): 50-GAATTTGCACCAGCAGACA-30).”
InfluentialFollowing the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.
Domvri, K., Darwiche, K., Zarogoulidis, P., & Zarogoulidis, P. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.06 · Cited by 32
“Epidermal growth factor receptor (EGFR) signaling is one of the major targets of NSCLC treatment, considering that EGFR overexpression is found in approximately 4080% of the patients (5).”
BackgroundShapiro, G. I., LoRusso, P. M., Cho, D. C., Musib, L. C., Yan, Y., Wongchenko, M. J., Chang, I., Patel, P. H., Chan, I. T., Bohorquez, S. M. S., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00975-6 · Cited by 32
“Several lines of evidence indicate crosstalk between the RAS/MEK/ERK and PI3K/AKT/mTOR pathways [16–18], with pharmacologic inhibition of RAS/RAF signaling leading to activation of PI3K/AKT signaling, and vice versa, through feedback loops [19].”
BackgroundAnnexin A6 is down-regulated through promoter methylation in gastric cancer.
Wang, X., Zhang, S., Zhang, J., Lam, E. K. Y., Liu, X., Sun, J., Feng, L., Lu, H., Yu, J. Q., & Jin, H. (2013) · Europe PMC (PubMed Central) · Cited by 32
Li, D., Jackson, R. A., Yusoff, P., & Guy, G. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.148445 · Cited by 48
Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy
Kee, H. J., & Cheong, J. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.3.273 · Cited by 35
“mTOR pathway constitutes a key cellular growth machinery, transducing signals to promote protein synthesis and cell cycle progression (65).”
BackgroundDarvin, P., Joung, Y. H., Sp, N., Kang, D. Y., Byun, H. J., Hwang, D., Cho, K. H., Park, K. D., Lee, H., & Yang, Y. M. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.03.020 · Cited by 33
Mammalian target of rapamycin complex 1 (mTORC1) signaling in energy balance and obesity
Cota, D. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.006 · Cited by 38
MicroRNAs: Modulators of theRasOncogenes in Oral Cancer
Murugan, A. K., Munirajan, A. K., & Alzahrani, A. S. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25269 · Cited by 34
“Active ras binds to p110a, a catalytic sub-unit of PI3K via ras binding domain (RBD) thereby directly activates PI3K (Bader et al., 2005; Shaw and Cantley, 2006).”
BackgroundYazawa, T., Shimizu, K., Kaira, K., Nagashima, T., Ohtaki, Y., Atsumi, J., Obayashi, K., Nagamori, S., Kanai, Y., Oyama, T., et al. (2015) · PubMed Central · Cited by 38
Wu, Z., Qi, Y., Guo, Z., Li, P., & Zhou, D. (2016) · BioScience Trends · doi:10.5582/bst.2016.01122 · Cited by 32
“The PI3K/Akt signaling pathway is a major signaling that promotes cell survival and proliferation (19).”
BackgroundDey, P. K., Son, J. Y., Kundu, A. B., Kim, K. S., Lee, Y., Yoon, K., Yoon, S., Lee, B. M., Nam, K. T., & Kim, H. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225622 · Cited by 32
Antagonism of mTOR Activity by a Kinetically Inert Rhodium(III) Complex
Zhong, H., Leung, K., Liu, L., Lu, L., Chan, D. S., Leung, C., & Ma, D. (2014) · ChemPlusChem · doi:10.1002/cplu.201400014 · Cited by 32
RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
Nyfeler, B., Chen, Y., Li, X., Pinzon-Ortiz, M. C., Wang, Z., Reddy, A., Pradhan, E., Das, R., Lehár, J., Schlegel, R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048548 · Cited by 33
“[1,2].”
An evaluation of sirolimus in renal transplantation
Halleck, F., Duerr, M., Waiser, J., Huber, L., Matz, M., Brakemeier, S., Liefeldt, L., Neumayer, H. ‐., & Budde, K. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.719874 · Cited by 34
“On top of its immunosuppressive qualities, SRL has anticancer activity by inhibition of growth factor-driven tumor cell proliferation, as seen in renal cell carcinoma, mantle cell lymphoma and prostate cancer [80,85].”
BackgroundHe, Y., Zhu, W., Shin, M. H., Gary, J. M., Liu, C., Dubois, W., Hoover, S. B., Jiang, S., Marrogi, E., Mock, B. A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.04.029 · Cited by 38
“The PI3K-AKTand RAS signaling pathways are two of the most common oncogenic signals in human cancers (Shaw and Cantley, 2006).”
BackgroundShin, M.-K., Payne, S., Bilger, A., Matkowskyj, K. A., Carchman, E. H., Meyer, D. S., Bentires‐Alj, M., Deming, D. A., & Lambert, P. F. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2843 · Cited by 31
“mTOR also acts as a downstream regulator of the PI3K–AKT signaling pathway; therefore mTOR signaling and its downstream pathway are also regulated by the PI3K/AKT signaling pathway (8).”
BackgroundWang, R., Zhang, D., Zhao, C., Wang, Q., Qu, H., & He, Q. (2019) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12174 · Cited by 31
Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador
Guevara‐Aguirre, J., Bautista, C., Torres, C. D., Peña, G., Guevara, C., Palacios, C. S., Guevara, A., & Gavilanes, A. W. D. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09602-4 · Cited by 37
New treatment options for advanced pancreatic cancer
Middleton, G., Ghaneh, P., Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.5.673 · Cited by 34
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.